COGT Cogent Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COGT

Price (delayed)

$31.41

Market cap

$5.45B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.16

Enterprise value

$5.51B

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed ...

Highlights
The company's net income fell by 33% YoY and by 6% QoQ
The company's equity fell by 12% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.unumrx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of COGT

COGT stock price

How has the Cogent Biosciences stock price performed over time
Intraday
-3.74%
1 week
-3.47%
1 month
-14.48%
1 year
142.74%
YTD
-11.57%
QTD
-18.84%

Financial performance

How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$389.09M
Net income
-$377.18M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 33% YoY and by 6% QoQ
COGT's operating income is down by 30% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does COGT's price correlate with its fundamentals

Growth

What is Cogent Biosciences's growth rate over time

Valuation

What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
10.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 4.3% YoY
The P/B is 162% above the 5-year quarterly average of 4.0 and 13% above the last 4 quarters average of 9.3
The company's equity fell by 12% QoQ

Efficiency

How efficient is Cogent Biosciences business performance
COGT's return on invested capital has surged by 66% year-on-year and by 20% since the previous quarter
The ROA has grown by 46% YoY and by 13% from the previous quarter
The company's return on equity rose by 40% YoY and by 13% QoQ

Dividends

What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COGT.

Financial health

How did Cogent Biosciences financials performed over time
Cogent Biosciences's total assets is 176% higher than its total liabilities
The total liabilities has surged by 152% year-on-year and by 2.3% since the previous quarter
Cogent Biosciences's quick ratio has decreased by 11% from the previous quarter
The company's debt is 54% lower than its equity
Cogent Biosciences's debt to equity has increased by 18% QoQ and by 18% YoY
The company's equity fell by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.